Publication Name	World Journal of Gastrointestinal Pharmacology and Therapeutics
Manuscript ID	122912
Country	India

Category	Gastroenterology & Hepatology
Manuscript Type	Correspondence
Article Title	Letter to the Editor: Can upadacitinib dose escalation redefine treatment strategies in refractory inflammatory bowel disease?
Manuscript Source	Invited Manuscript
All Author List	Himanshu Agrawal and Nikhil Gupta
Funding Agency and Grant Number
Corresponding Author	Nikhil Gupta, Department of Surgery, Atal Bihari Vajpayee Institute of Medical Sciences and Dr. Ram Manohar Lohia Hospital, BKS Marg, Delhi 110001, India. nikhil_ms26@yahoo.co.in
Key Words	Inflammatory bowel disease; Upadacitinib; Dose escalation; Janus kinase inhibitors; Treatment resistance; Personalized medicine; Ulcerative colitis; Crohn’s disease
Core Tip	Upadacitinib dose escalation may provide symptomatic benefit and reduce corticosteroid dependence in selected patients with refractory inflammatory bowel disease who experience secondary loss of response. The findings of Ellington et al support a more flexible and individualized approach to therapeutic optimization while emphasizing the need for careful safety monitoring and prospective validation.
Citation	Agrawal H, Gupta N. Letter to the Editor: Can upadacitinib dose escalation redefine treatment strategies in refractory inflammatory bowel disease? World J Gastrointest Pharmacol Ther 2026; In press

Received	2026-05-08 06:02
Peer-Review Started	2026-05-08 06:02
First Decision by Editorial Office Director	2026-05-15 11:37
Return for Revision	2026-05-15 11:37
Revised	2026-05-18 10:53
Publication Fee Transferred
Second Decision by Editor	2026-06-01 02:41
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2026-06-01 09:09
Articles in Press	2026-06-01 09:09
Edit the Manuscript by Language Editor
Typeset the Manuscript

ISSN	2150-5349 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc.
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com